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ABSTRACT
Objective Using whole genome sequencing, we
identiﬁed gene ampliﬁcation of solute carrier family 12
member 5 (SLC12A5) located at 20q13.12 in colorectal
cancer (CRC). We analysed its ampliﬁcation,
overexpression, biological effects and prognostic
signiﬁcance in CRC.
Design SLC12A5 ampliﬁcation status was evaluated by
ﬂuorescence in situ hybridisation (FISH). The effects of
SLC12A5 re-expression or knockdown were determined
in proliferation, apoptosis, invasion and metastasis
assays. SLC12A5 target genes and related pathways
were identiﬁed by reporter activity and cDNA microarray
analyses. Clinical impact of SLC12A5 overexpression was
assessed in 195 patients with CRC.
Results Ampliﬁcation of SLC12A5 was veriﬁed in 78
out of 191 (40.8%) patients with primary CRC by FISH,
which was positively correlated with its protein
overexpression (p<0.001). Biofunctional investigation of
SLC12A5 revealed that SLC12A5 signiﬁcantly increased
cell proliferation, G1-S cell cycle transition, invasion/
migration abilities, but suppressed apoptosis in vitro and
promoted xenograft tumour growth as well as lung
metastasis in vivo. The antiapoptosis effect by SLC12A5
was mediated through inhibiting apoptosis-inducing
factor and endonuclease G-dependent apoptotic
signalling pathway; and the pro-metastasis role was by
regulating key elements of the matrix architecture,
including matrix metallopeptidase and ﬁbronectin. After
a median follow-up of 50.16 months, multivariate
analysis revealed that patients with SLC12A5 protein
overexpression had a signiﬁcant decrease in overall
survival. Kaplan–Meier survival curves showed that
SLC12A5 overexpression was signiﬁcantly associated
with shortened survival in patients with CRC.
Conclusions SLC12A5 plays a pivotal oncogenic role
in colorectal carcinogenesis; its overexpression is an
independent prognostic factor of patients with CRC.
INTRODUCTION
Colorectal cancer (CRC) is the third most com-
monly diagnosed cancer in men and the second in
women worldwide.1 In Asian countries, the inci-
dence of CRC has been rising rapidly.2
Approximately 50%–60% of patients diagnosed
with CRC develop metastases, which is the main
cause of mortality in patients with CRC.3 4 The
pathogenic mechanisms underlying CRC develop-
ment appear to be complex and heterogeneous.
Emerging evidences indicate that CRC develop-
ment is a multistep process with the accumulation
of genetic and epigenetic alterations.5 Copy
number aberrations (CNAs), including chromosome
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Signiﬁcance of this study
What is already known on this subject?
▸ SLC12A5, a gene located at 20q13.12, belongs
to the SLC12 gene family and encodes the
protein of solute carrier family 12, member 5.
▸ Gene ampliﬁcation is one of the most common
mechanisms which contributes to
overexpression of genes favouring tumour
development.
What are the new ﬁndings?
▸ SLC12A5 ampliﬁcation is identiﬁed for the ﬁrst
time in colorectal cancer (CRC) by whole
genome sequencing. We have further veriﬁed
SLC12A5 ampliﬁcation by ﬂuorescence in situ
hybridisation in 78 out of 191 (40.8%) patients
with primary CRC.
▸ SLC12A5 plays strong tumourigenic role
through inhibiting apoptosis and promoting
metastasis evidenced by in vitro and in vivo
tumorigenicity experiments.
▸ SLC12A5 inhibits apoptosis through
suppressing apoptosis-inducing factor/
endonuclease G-dependent apoptotic signalling
and promotes metastasis through regulating
key elements of the matrix architecture.
▸ SLC12A5 overexpression mediated by
ampliﬁcation is associated with poor prognosis
of patients with CRC.
How might it impact on clinical practice in
the foreseeable future?
▸ Detection of SLC12A5 overexpression may serve
as a new biomarker for the prognosis of
patients with CRC.
Xu L, et al. Gut 2016;65:635–646. doi:10.1136/gutjnl-2014-308257 635
Colon
group.bmj.com on January 2, 2017 - Published by http://gut.bmj.com/Downloaded from 
gains and losses, or localised ampliﬁcations and deletions, are
frequently found in human CRC and are major causes of aber-
rant activation of oncogenes and inactivation of tumour sup-
pressor genes.6–10 Some CNAs, such as copy number loss of
chromosome 18q12.2, copy number gain at the chromosomal
region between 11q13.3 and 11q22.3, gene ampliﬁcation of
MPL1/PZR, are closely related to clinical outcome or metastatic
progression.11–16 It is of great importance to identify and func-
tionally characterise novel genes with CNAs that are associated
with CRC.
It is well documented that CNAs on chromosome 20 are involved
in human cancers. 20q13.12 is one of the most frequently ampliﬁed
regions in CRC, as well as in other human cancers, which contains
several putative oncogenes.17–21 Our recent study using single-cell
sequencing demonstrated an activating point mutation of solute
carrier family 12 member 5 (SLC12A5), a gene located at
20q13.12, in CRC.22 Targeted capture sequencing in a larger
cohort of patients with CRC revealed that the mutation prevalence
of SLC12A5 is only 3.8% (7 out of 182 cases).23 We found that
SLC12A5 was widely expressed in CRC tissues, while silenced or
downregulated in their adjacent mucosal tissues. We, therefore,
hypothesised that ampliﬁcation of SLC12A5 could be an important
mechanism for its activation. Indeed, using whole-genome sequen-
cing, we identiﬁed the frequent ampliﬁcation of SLC12A5 in
human CRC. This was conﬁrmed by an analysis of CRC genomic
data of The Cancer Genome Atlas (TCGA), showing the frequent
ampliﬁcation of SLC12A5 in CRC cases (https://www.synapse.org/
#!Synapse:syn300013).
SLC12A5, also known as potassium chloride cotransporter 2,
belongs to the SLC12 gene family and encodes the protein of
solute carrier family 12, member 5.24 SLC12A5 protein is an
integral membrane KCl cotransporter that maintains chloride
homeostasis in neurons.25 26 However, the role of SLC12A5
ampliﬁcation in CRC has not yet been explored. In this study,
we evaluated the ampliﬁcation status of SLC12A5, characterised
the functional mechanisms and the clinical implication of
SLC12A5 in colorectal carcinogenesis.
MATERIALS AND METHODS
Tissue samples
CRC tissue microarrays (TMAs) were constructed according to
a method described previously.27 The ﬁrst set of TMA was
generated from formalin-ﬁxed, parafﬁn-embedded archive
tissues of 191 patients with CRC, which were collected at The
Prince of Wales Hospital, Hong Kong, from 2002 to 2010. The
second set of TMAs was prepared from 195 CRC tissues, which
were obtained from the Sun Yat-Sen University and Guangdong
Provincial People’s Hospital, Guangzhou, China, between
January 2000 and November 2006. The patient’s demographic
and clinicopathological features were shown in table 1 and
online supplementary table S1. The TNM status of CRCs was
assessed according to the criteria of the sixth edition of the
TNM classiﬁcation of the International Union Against Cancer
(2002).28 Patients were being regularly followed up and the
median follow-up duration since the time of diagnosis was
50.16 months (range 7–60 months). In addition, 15 paired
primary tumour and adjacent non-tumour tissues from patients
with CRC were obtained during operation prior to any thera-
peutic intervention at the Prince of Wales Hospital in Hong
Kong. All subjects provided informed consent for obtaining the
study specimens.
Fluorescence in situ hybridisation
The bacterial artiﬁcial chromosome clone RP11-465L10 at
20q13.12 containing SLC12A5 gene was labelled with
Sperctrum-Red (Vysis, Downers Grove, Illinois, USA).
Chromosome 20 centromere probe labelled with
Spectrum-Green (Vysis) was used as control. For cell line ﬂuor-
escence in situ hybridisation (FISH), metaphase cells were col-
lected after colcemid treatment, followed by hypotonic
treatment and ﬁxation, then were spread on slides. For tissue
FISH, parafﬁn-embedding TMA sections were pretreated by
de-waxing, gradient hydration and Proteinase K digestion. The
Probes hybridisation procedure was performed according to the
previous method.29
Statistical analysis
The results were expressed as mean±SD. Statistical analysis was
performed using the SPSS statistical software package (standard
V.16.0). The Pearson correlation coefﬁcient was used to evaluate
the correlation between SLC12A5 gene ampliﬁcation and
expression in the clinical samples. The χ2 test was used for com-
parison of patient characteristics and distributions of expression
and covariates by vital status. Crude relative risks (RRs) of death
Table 1 Relationship between SLC12A5 expression and clinicopathological features in 195 colorectal cancer cases
Variable Low expression (n=125) Per cent High expression (n=70) Per cent p Value
Mean age, years±SD 56.6±12.6 59.3±11.4 0.86
Gender 0.13
F 55 70.5 23 29.5
M 70 59.8 47 40.2
Location 0.39
Colon 99 62.7 59 37.3
Rectal 26 70.3 11 29.7
Grade 0.65
High 13 72.2 5 27.8
Moderate 93 62.4 56 37.6
Low 19 67.9 9 32.1
TNM stage 0.03
I 46 63.0 27 37.0
II 50 74.6 17 25.4
III 25 58.1 18 41.9
IV 4 33.3 8 66.7
The TNM Staging System is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M).
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associated with SLC12A5 expression and other predictor vari-
ables were estimated by univariate Cox proportional hazards
regression model ﬁrst. Multivariate Cox model was constructed
to estimate the adjusted RR for SLC12A5 expression. Overall
survival in relation to expression was evaluated by the Kaplan–
Meier survival curve and the log-rank test. Mann–Whitney U
test or Student’s t test was performed to compare the variables
of two groups. The difference in cell viability and tumour
growth rate between the two groups of nude mice was deter-
mined by repeated-measures analysis of variance. p Values
<0.05 were taken as statistical signiﬁcance. Additional detailed
description of the materials and methods can be found in the
online supplementary materials and methods section.
RESULTS
Ampliﬁcation of SLC12A5 is identiﬁed in CRCs
We evaluated SLC12A5 protein expression in 15 pairs of colo-
rectal tumours and adjacent normal tissues by immunohisto-
chemistry. SLC12A5 protein expression was distributed in both
nuclear and cytoplasm of CRC tumour cells in 93% of CRCs
(14/15), but not in normal colon tissue cells (ﬁgure 1A). The
protein expression level of SLC12A5 was signiﬁcantly higher in
primary CRCs as compared with their adjacent normal tissues
(p<0.05) (ﬁgure 1B). We performed immunoﬂuorescence and
confocal microscopy of colon cancer cell line HCT116 and con-
ﬁrmed that the SLC12A5 protein expression was distributed in
both nuclear and cytoplasm (ﬁgure 1C). As activating mutation
of SLC12A5 was only detected in 3.8% (7 out of 182 cases)
CRCs by targeted capture sequencing,23 other mechanisms such
as gene ampliﬁcation may contribute to the enhanced expression
of SLC12A5.
By whole-genome sequencing analyses, we identiﬁed SCL12A5
ampliﬁcation in CRC (ﬁgure 1D), which was conﬁrmed by array
comparative genomic hybridisation showing copy number gain
of SLC12A5 (see online supplementary table S2). To further
conﬁrm our identiﬁcation, we evaluated the copy number vari-
ation from TCGA data (https://www.synapse.org/#!Synapse:
syn300013). In TCGA cohort of 575 CRCs, SLC12A5 was
ampliﬁed in both colon cancer (q value=8.99E-07, frequency=
72.6%) and rectal cancer (q value=0.003, frequency=88.9%),
signifying its common occurrence in CRC (ﬁgure 1E, F).
Ampliﬁcation of SLC12A5 contributes to its overexpression
in CRC tumour tissues
To examine the relationship between DNA ampliﬁcation of
SLC12A5 and its overexpression, the DNA copy number change
of SLC12A5 was investigated by FISH in a TMA containing 191
CRC cases. Ampliﬁcation of SLC12A5 was not observed in
normal metaphase lymphocytes, but detected in colon cancer
cell line Caco-2 (ﬁgure 2A). Importantly, 40.8% (78/191) of
primary CRCs exhibited ampliﬁcation of SLC12A5, while there
was no obvious copy number gain in adjacent normal tissues
(ﬁgure 2B). The protein expression of SLC12A5 was investi-
gated in the same TMA by immunohistochemistry (ﬁgure 2C).
Pearson correlation analysis indicated that ampliﬁcation of
SLC12A5 in CRC tissues was positively correlated with its
protein overexpression (p<0.001) (ﬁgure 2D). These data
suggest that upregulation of SLC12A5 protein in CRC is at least
in part contributed by DNA ampliﬁcation.
SLC12A5 promotes CRC cell growth in vitro and in vivo
To assess the potential function of SLC12A5, a series of in vitro
biological experiments were performed with gain-of-function or
loss-of-function of SLC12A5. SW480 and SW116 cells were
stably transfected with different doses of SLC12A5 plasmids.
Ectopic expression of SLC12A5 in these cells (ﬁgure 3A) caused
a signiﬁcant increase in the number of viable cells in a dose-
dependent fashion in SW480 and SW1116 (p<0.01) compared
with empty vector transfected cells, respectively (ﬁgure 3B). In
keeping with this, the number of colonies increased signiﬁcantly
in a dose-dependent manner when transfected with SLC12A5
plasmids compared with empty vector-transfected SW480 and
SW1116, respectively (ﬁgure 3C, D). On the other hand, we
examined whether SLC12A5 is required for the tumourigenic
phenotypes of CRC cells by silencing SLC12A5 expression with
siRNA. The introduction of SLC12A5-speciﬁc siRNA
(siSLC12A5) into HCT116 dramatically decreased the expres-
sion of SLC12A5 relative to control cells transfected with
scrambled siRNA (ﬁgure 3E). SLC12A5 depletion by siRNA
reversed the tumourigenic phenotype by inhibiting the cell
growth rate compared with control cells (p<0.001) (ﬁgure 3F).
To further investigate the in vivo tumourigenic ability of
SLC12A5, we constructed a lentiviral vector carrying
shSLC12A5 to stably knock down the expression of SLC12A5
in HCT116 (ﬁgure 3G). The Control-HCT116 and
shSLC12A5-HCT116 cells were injected subcutaneously into
the dorsal ﬂank of nude mice. Tumours induced by
shSLC12A5-HCT116 cells showed signiﬁcantly longer latency
and smaller mean tumour volume than tumours induced by
control cells (p<0.001) (ﬁgure 3H). At the end of experiments,
xenograft tumours were isolated and the mean tumour weight
of the shSLC12A5-HCT116 group was reduced by more than
70% as compared with controls (p<0.05) (ﬁgure 3I).
Collectively, these data indicate that SLC12A5 possesses strong
tumourigenicity in CRC both in vitro and in vivo.
SLC12A5 inhibits apoptosis in colon cancer cells
To explore the molecular basis involved in SLC12A5-enhanced
tumour growth, the effect of SLC12A5 on apoptosis was
assessed quantitatively by ﬂow cytometry after staining with
Annexin V and 7-amino-actinomycin. We found that overexpres-
sion of SLC12A5 signiﬁcantly inhibited early apoptosis in
SW480 and SW1116 (p<0.001) (ﬁgure 4A), as compared with
control vector-transfected cells. To further clarify whether
knockdown of SLC12A5 could reverse this phenotype, siRNAs
against SLC12A5 were transfected into HCT116 cells. The per-
centage of early apoptotic cells in siSLC12A5 HCT116 cells
was signiﬁcantly increased, as compared with the control cells
(p<0.01) (ﬁgure 4B).
SLC12A5 exerts an antiapoptotic function through
the caspase-independent pathway
To deﬁne the molecular basis of cell death after SLC12A5 deple-
tion, we assessed the key apoptosis regulators. Activation of cas-
pases and the subsequent cleavage of poly (ADP-ribose)
polymerase (PARP) are classic molecular hallmarks of apop-
tosis.30 However, no changes of cleaved Caspase 3, 7 or cleaved
PARP were observed after silencing SLC12A5 expression
(ﬁgure 4C), indicating that SLC12A5 may inhibit apoptosis via
a caspase-independent pathway. Apoptosis-inducing factor (AIF)
and endonuclease G (EndoG) are known for mediating cell
death independent of caspases by translocating from mitochon-
dria into the nucleus where they induce DNA cleavage.30 We,
therefore, examined the nuclear protein expression of AIF and
EndoG. We found that knockdown of SLC12A5 enhanced the
nuclear protein levels of AIF and EndoG (ﬁgure 4C). The mito-
chondrial release of AIF and EndoG is mediated by
pro-apoptotic Bax and Bak and their upstream regulators, p53
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Figure 1 SLC12A5 is ampliﬁed in colorectal cancer (CRC). (A) Representative images of SLC12A5 protein expression in CRC tumour tissues and
their adjacent tissues by immunohistochemistry. (B) The protein expression level of SLC12A5 was signiﬁcantly higher in primary CRC tumour as
compared with their adjacent tissue (p<0.05). (C) SLC12A5 was expressed in both nuclear and cytoplasm in colon cancer cell line HCT116 by
immunoﬂuorescence and confocal microscopy. (D) The right panel shows the genomic proﬁles of CRC by whole genome sequencing, where the copy
number alterations were indicated with red bars. The left panel shows the visualisation of copy ratio particularly for the whole chromosome 20.
20q13.12 is highlighted with red colour, which harbours the ampliﬁed gene SLC12A5. (E) Signiﬁcant genomic alterations of 20q13.12 across 12
human cancer types in The Cancer Genome Atlas (TCGA) cohort. Red colour indicates copy number gain, while blue colour refers to copy number
loss. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; KIRC, kidney renal clear cell carcinoma; COAD, colon adenocarcinoma;
DAPI, 4’,6-diamidino-2-phenylindole; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; LAML, acute myeloid
leukaemia; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; READ, rectum adenocarcinoma; OV, ovarian serous
cystadenocarcinoma; UCEC, uterine corpus endometrioid carcinoma. (F) Copy number changes of SLC12A5 in 575 colorectal cancers from TCGA.
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and p53 upregulated modulator of apoptosis (PUMA), which
can inﬂuence the mitochondrial membrane permeabilisation.31
Concordantly, SLC12A5 silencing increased the protein
expression of pro-apoptotic factors p53, PUMA, Bax and Bak
(ﬁgure 4C). Emerging evidence supported the fact that the
inhibitor of apoptosis protein Survivin decreases the amount of
AIF in the nucleus after apoptosis induction, thus protecting cells
from death.32 33As shown in ﬁgure 4C, Survivin was signiﬁcantly
downregulated after knockdown of SLC12A5. To further
conﬁrm the antiapoptotic effect of SL12A5 in vivo, we
performed TUNEL staining on the parafﬁn slides of mouse
xenograft tumours. We found that TUNEL-positive apoptosis cells
were signiﬁcantly more in the shSLC12A5-HCT116 tumours
compared with the control-HCT116 tumours (p<0.01)
(ﬁgure 4D). Consistently, the nuclear protein expression of AIF
and EndoG was signiﬁcantly increased in the shSLC12A5-
HCT116 tumours compared with the control-HCT116 tumours
(ﬁgure 4D), which is consistent with the in vitro study by western
blot (ﬁgure 4C). These results collectively suggest that SLC12A5
inhibits apoptosis by suppressing the activation of AIF–
EndoG-dependent apoptotic pathway (ﬁgure 4E).
SLC12A5 promotes G1 to S phase transition in colon
cancer cells
To characterise the oncogenic mechanism of SLC12A5 in colon
cancer cell growth, we further investigated the role of
SLC12A5 in cell cycle progression. We found that ectopic
expression of SLC12A5 in SW480 (SLC12A5-SW480) signiﬁ-
cantly decreased the number of cells in G1 phase (p<0.01),
but increased the number of cells in S phase (p<0.01) com-
pared with control vector-transfected cells 12 h after serum
stimulation (ﬁgure 4F). Conversely, knockdown SLC12A5 in
HCT116 cells by siSLC12A5 arrested the cell cycle at the
G1–S transition (p<0.01) (ﬁgure 4F). Western blot analysis
showed that the protein expression of two master G1–S check-
point regulators cyclin D1 and cyclin-dependent kinase
(CDK4) was increased in SLC12A5-SW480 compared with the
vector-transfected cells, while knockdown SLC12A5 in
HCT116 had the opposite effect (ﬁgure 4G), conﬁrming the
role of SLC12A5 on promoting cell growth by regulating cell
cycle progression in colon cancer cells.
SLC12A5 inhibits p53 and p21 reporter activity
To gain insights into the downstream signalling pathways modu-
lated by SLC12A5 in CRC tumourigenesis, we examined the
functional effect of SLC12A5 in several important cancer path-
ways, including p53, p21, activator protein-1 (AP-1), nuclear
factor (NF)-κB and Wnt/β-catenin (TOPFlash), by luciferase
reporter activity assay. Ectopic expression of SLC12A5 signiﬁ-
cantly suppressed p53 and p21 luciferase reporter activities in
HCT116 (ﬁgure 5A), whereas no signiﬁcant activity changes
were observed in AP-1, NFκB and Wnt/β-catenin pathway repor-
ters (ﬁgure 5A). To further conﬁrm the importance of the p53
and p21 pathways mediated by SLC12A5 in colon cancer cells,
we assessed the ability of abolishing SLC12A5 in the reporter
activities of p53 and p21. Knockdown SLC12A5 signiﬁcantly
enhanced p53 and p21 reporter activities (ﬁgure 5B). Western
blot results further validated that ectopic expression of SLC12A5
reduced the protein level of p53 and p21, while knockdown of
SLC12A5 upregulated p53 and p21 in HCT116 cells (ﬁgure 5C).
As SLC12A5 promoted cell proliferation and inhibited cell
apoptosis in p53-mutated cells SW480 and SW1116, which
implies the tumour-promoting function of SLC12A5 could be
independent of p53. To conﬁrm this hypothesis, we transfected
Figure 2 Ampliﬁcation and overexpression of SLC12A5 in colorectal cancers (CRCs). (A) Fluorescence in situ hybridisation (FISH) was performed in
normal metaphase lymphocytes and colon cancer cell line Caco-2. The red signal indicates the location of SLC12A5 and the green signal refers to
centromere of chromosome 20. This result implied that the probe of SLC12A5 was correctly located on chromosome 20. Ampliﬁcation of SLC12A5
was observed in Caco-2. (B) Representative image of SLC12A5 gene ampliﬁcation detected by FISH in primary CRC tissues, but not detected in their
adjacent tissues. (C) Representative staining of high and low expression levels of SLC12A5 in CRC tissue microarray slides by immunohistochemistry.
(D) The correlation between copy number changes of SLC12A5 and protein overexpression (R2=0.506, p<0.001).
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SLC12A5 in p53 knockout (KO) HCT116 cells (ﬁgure 5D).
Ectopic expression of SLC12A5 signiﬁcantly enhanced cell
growth in p53 KO HCT116 cells (ﬁgure 5E). We then deter-
mined the above ﬁve luciferase reporters in p53 KO HCT116
and SW1116. As shown in ﬁgure 5F, only p21 reporter activity
was signiﬁcantly downregulated. These data indicated that
SLC12A5 suppressed p21 activity irrespective of p53 status.
SLC12A5 promotes tumour invasion and metastasis in vitro
and in vivo
We also investigated the effects of SLC12A5 on metastasis using in
vitro migration and Matrigel invasion assays and in vivo metastasis
assay. The migration and Matrigel invasion assays showed that both
the migration and the invasive capability of SLC12A5-SW1116 cells
were greater than those of Vector-SW116 cells (ﬁgure 6A). By con-
trast, knockdown SLC12A5 expression by siRNA in HCT116 cells
eliminated the migratory and invasive ability of the HCT116 cells
(ﬁgure 6B). These results indicate that SLC12A5 increases cell inva-
sion and metastasis, which we further validated in vivo.
The in vivo metastasis assay was performed by injecting HCT116
cells transduced with shSLC12A5 or Control-shRNA into nude mice
through the lateral tail vein to examine the cells’ lung metastasis
ability. Six weeks following injection, the incidence of lung metastases
(5/5, 100%) was signiﬁcantly higher in mice injected with Control-
Figure 3 SLC12A5 promotes
colorectal cancer cell growth.
(A) Expression levels of SLC12A5 were
increased after transfection with
different doses of SLC12A5 plasmids
(0.8 and 1.6 mg) in colon cancer cell
lines SW480 and SW1116. (B) Ectopic
expression of SLC12A5 signiﬁcantly
enhanced cell viability in a
dose-dependent manner in both cell
lines. (**p<0.01, ***p<0.001)
(C) Empty vector and different doses of
SLC12A5 plasmids (0.8 and 1.6 mg)
were used to transfect cells in 24-well
plates. Compared with empty
vector-transfected cells, colony
numbers signiﬁcantly increased with
transfection of 0.8 and 1.6 mg
SLC12A5 plasmids in SW480 in a
dose-dependent manner. (D) The
number of colonies increased in a
dose-dependent manner when
transfected with SLC12A5 plasmids in
SW1116. (E) Knockdown efﬁciency of
SLC12A5 in HCT116 cells by transient
transfection of siSLC12A5 was
examined by real-time PCR (left panel)
and western blot (right panel),
respectively. (F) Knockdown of
SLC12A5 signiﬁcantly inhibited cell
viability in HCT116. (G) Knockdown
efﬁciency of SLC12A5 in HCT116 cells
by stable transfection of shSLC12A5
was demonstrated by real-time PCR
(left panel) and western blot (right
panel). (H) The tumour growth curve
of HCT116 stably transduced with
shSLC12A5 in nude mice was
signiﬁcantly dampened compared with
HCT116 transduced with Control.
(I) A representative picture of tumour
formation in nude mice subcutaneously
inoculated with shSLC12A5- or
Control-HCT116 (left panel). Histogram
represents mean of the tumour weight
from the shSLC12A5 and Control
groups (right panel).
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HCT116 cells than in mice injected with shSLC12A5-HCT116 cells
(1/5, 20%) (p<0.01) (ﬁgure 6C). Metastatic nodules in the lungs
were conﬁrmed histologically (ﬁgure 6C).
SLC12A5 regulates extracellular matrix remodelling genes
To gain further insight into the mechanisms by which SLC12A5
promotes CRC cell invasion and metastasis,
SLC12A5-modulated downstream target genes were charac-
terised by Human Tumour Metastasis RT2 Proﬁler PCR array in
HCT116 cells transfected with siSLC12A5 or control siRNA.
The results showed that knockdown of SLC12A5 in HCT116
cells upregulated nine antimetastasis genes, including metastasis
suppressor (MTSS1), p53, NME/NM23 nucleoside diphosphate
kinase (NME1), ﬁbronectin 1 (FN1), neuroﬁbromin 2, FAT
tumour suppressor homologue 1 (FAT1), breast cancer metastasis
suppressor 1 (BRMS1), tissue inhibitor of metalloproteinase 2
(TIMP2), cathepsin K (CTSK) and downregulated four pro-
metastasis genes, namely matrix metallopeptidase 2 (MMP2),
hepatocyte growth factor (HGF), MMP 13 and MMP10, as com-
pared with Control-HCT116 cells, with more than a twofold
change at mRNA levels (see online supplementary table S3).
Selected downstream effectors of SLC12A5 were validated in
two more colon cancer cell lines by overexpression of SLC12A5.
Consistent with the array data, ectopic expression of SLC12A5 in
Figure 4 SLC12A5 reduces apoptosis
in colorectal cancer cell lines.
(A) Overexpression of SLC12A5
signiﬁcantly inhibited early apoptosis
in SW480 and SW1116 (B) Knockdown
of SLC12A5 signiﬁcantly increased the
proportion of apoptotic cells in
HCT116 cells by ﬂow cytometry
analyses following Annexin V and
7-amino-actinomycin (7-AAD) staining
(p<0.01). (C) Protein expression of key
apoptosis-related genes was evaluated
by western blot in HCT116 cells
transfected with siSLC12A5 or Control.
After silencing SLC12A5 expression, no
changes of cleaved Caspase 3, 7 nor
cleaved poly(ADP-ribose) polymerase
(PARP) were observed. SLC12A5
silencing increased the protein
expression of p53, p53 upregulated
modulator of apoptosis (PUMA), Bax
and Bak and downregulated the
inhibitor of apoptosis protein Survivin.
Knockdown of SLC12A5 enhanced the
nuclear protein levels of
apoptosis-inducing factor (AIF) and
endonuclease G (EndoG).
(D) TUNEL-stained sections of mouse
xenograft tumours displayed apoptotic
cells; representative images of AIF and
EndoG immunohistochemistry-stained
sections of mouse xenograft tumours.
(E) Schematic diagram for the
proposed mechanisms of SLC12A5
exerting antiapoptotic function via
caspase-independent signalling
pathway. (F) The number of cell
distribution was determined by ﬂow
cytometry. Values are mean±SD.
(G) Protein expression of cyclin D1 and
cyclin-dependent kinase (CDK4) was
determined by western blot.
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SW480 and SW1116 downregulated MTSS1 and FN1, but upre-
gulated MMP2, HGF and MMP13 as determined by RT-PCR
and western blots (ﬁgure 6D, E). Taken together, our ﬁndings
strongly suggest that SLC12A5 promote invasion and metastasis
by regulating extracellular matrix-remodelling genes.
Overexpression of SLC12A5 is associated with poor
prognosis of patients with CRC
We further evaluated the clinicopathological and prognostic
signiﬁcance of SLC12A5 in patients with CRC. As shown in
table 1, overexpression of SLC12A5 was positively associated
with a more advanced TNM stage (p<0.05), which is consistent
with the role of SLC12A5 on tumour metastasis. Kaplan–Meier
survival analysis showed that patients with CRC with SLC12A5
overexpression had signiﬁcantly shorter survival compared with
those with SLC12A5 low expression (p=0.009, log-rank test)
(ﬁgure 7). In univariate Cox regression analysis, SLC12A5 over-
expression was associated with an increased risk of cancer-
related death (RR, 2.38; 95% CI 1.21 to 4.66; p=0.012)
(table 2). After the adjustment for potential confounding
factors, multivariate Cox regression analysis showed that
SLC12A5 overexpression was an independent predictor of
poorer survival of patients with CRC (RR, 2.30; 95% CI 1.16
to 4.60; p=0.018) (table 2).
DISCUSSION
In this study, ampliﬁcation of SLC12A5 was detected in 40.8%
(78/191) of primary CRCs by FISH, but not in their adjacent
tissues. Compared with the low frequency of SLC12A5 point
mutation (3.8%) reported in our recent study based on targeted
capture sequencing,23 ampliﬁcation of SLC12A5 is a common
event in colorectal tumourigenesis. SLC12A5 was located on
chromosome 20q13.12, which is one of the most frequently
ampliﬁed regions in CRC21 and in other cancer types such as
breast, ovarian and gastric cancers.19 20 The 20q13.12 amplicon
encodes 11 genes, none of which have been unequivocally
described with oncogenic function in CRC yet.21 Gene ampliﬁ-
cation is thought to promote overexpression of genes favouring
tumour development.34 35 Importantly, we revealed that the
ampliﬁcation of SLC12A5 was positively associated with its
protein overexpression in the 191 CRC cases (p<0.001), sug-
gesting that increased SLC12A5 copy number contributes to the
up-regulation of SLC12A5, which might play an important
oncogenic role in CRC. In keeping with our ﬁnding, SLC12A5
was upregulated in cervical cancer.36
A series of in vitro and in vivo functional experiments
revealed that SLC12A5 possessed a strong tumourigenic func-
tion in CRC. SLC12A5 enhanced tumour cell survival, which is
attributable to its antiapoptotic and pro-proliferative ability.
Defective apoptosis is one of the hallmarks of cancer. Although
caspase activation is considered a cardinal feature of apoptosis,37
an alternative pathway of apoptosis has been described that does
not require caspase activation, which is characterised by the
nuclear translocation of AIF and EndoG.30 38 39 In this study,
knockdown of SLC12A5 induced apoptosis without caspase
activation, suggesting that SLC12A5 modulated apoptosis via a
caspase-independent pathway. In line with this hypothesis, we
found that silencing SLC12A5 enhanced the nuclear protein
levels of AIF and EndoG (ﬁgure 4). The release of AIF and
EndoG is regulated by mitochondrial outer membrane
Figure 5 SLC12A5 suppressed p53
and p21 luciferase reporter activity.
(A) To screen for SLC12A5 target
signalling pathways, a serial of
promoter-luciferase assays (p53-luc,
p21-luc, activator protein 1 (AP1)-luc,
nuclear factor κB (NF κB)-luc, and
Wnt/β-catenin) were performed in
SLC12A5 stably transfected p53
wildtype (WT) HCT116 cells compared
with vector control cells. Luciferase
activities were determined by dual
luciferase assay system at 48 h
post-transfection. Ectopic expression of
SLC12A5 suppressed p53 and p21
luciferase reporter activity in p53 WT
HCT116. (B) Knockdown of SLC12A5
increased p53 and p21 luciferase
reporter activity in p53 WT HCT116.
(C) The western blot results conﬁrmed
the ﬁndings of luciferase reporter
activity assays in p53 WT HCT116.
(D) Ectopic expression of SLC12A5 was
determined in p53 knockout (KO)
HCT116 cells by real-time PCR.
(E) Ectopic expression of SLC12A5
signiﬁcantly promoted cell growth in
p53 KO HCT116 cells. (F) SLC12A5 in
HCT116 cells suppressed p21-luciferase
reporter activity in both p53 KO
HCT116 and SW116 cells.
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permeability, which is modulated by the relative abundance of
the pro-apoptotic Bax and Bak.31 After being activated by p53,
PUMA interacts with antiapoptotic Bcl-2 family members,
thereby freeing pro-apoptotic molecules, Bax and Bak.30
Consistent with the antiapoptotic role of SLC12A5, nuclear
translocation of AIF and EndoG by silencing SLC12A5 was par-
alleled with the upregulation of p53, PUMA, Bax and Bak. Bax
and Bak can form complexes at the mitochondrial outer mem-
brane to facilitate the release of AIF and EndoG into nucleus.40
On the other hand, the inhibitor of apoptosis protein Survivin
retrains AIF in mitochondria and suppresses AIF activity, thus
further enhancing apoptotic resistance.32 Collectively, our data
support that SLC12A5 inhibits caspase-independent apoptosis
by deregulating AIF and EndoG in CRC (ﬁgure 4E). Cell cycle
analysis revealed a decrease in G1 phase cells and an increase in
S phase cells in SLC12A5-transfected cells, and a concomitant
increase of protein expression of the master G1–S transition reg-
ulators cyclin D1 and CDK4. These results indicated that
SLC12A5 could facilitate DNA synthesis and promote G1–S
transition, contributing to its oncogenic effect in CRC.
Moreover, SLC12A5 inhibited p53 and p21 luciferase
reporter activities in HCT116, which is p53 wild type. p53 and
p21 were implicated in apoptosis,30 and the inhibition of these
factors may contribute to the antiapoptotic effect of SLC12A5.
Consistent with this effect, it has been reported that supplemen-
tation of KCl in extracellular medium was most effective in pre-
venting hypoxia-induced apoptosis.41 It is further revealed that
KCl supplementation downregulated a distinct p53-regulated
cellular sub-network of genes involved in regulation of DNA
replication.41 On the other hand, SLC12A5 also exhibited
Figure 6 SLC12A5 promotes tumour metastasis in vitro and in vivo. (A) Ectopic expression of SLC12A5 promoted cell invasion and migration in
SW1116 cells. (B) Knockdown of SLC12A5 suppressed cell invasion and migration in HCT116 cells. (C) Representative images of lungs with or
without metastasis (left panel). H&E staining of lung tissues from nude mice injected with Control-HCT116 or shSLC12A5-HCT116 cells (200x
magniﬁcation, middle panel). Incidence of lung metastasis (right panel). (D) Validation of the key metastasis-related genes identiﬁed by cDNA
expression array by RT-PCR. (E) Western blot further conﬁrmed the deregulation of metastasis-related genes. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; HGF, hepatocyte growth factor; MMP, matrix metallopeptidase.
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tumour-promoting effect and suppressed p21 reporter activity
in p53 KO and mutated CRC cells, indicating that SLC12A5
promotes tumourigenesis by inhibiting p21 reporter activity
regardless of p53 status. In line with this, the carboxyl terminus
of p21 was reported to activate cell apoptosis without caspase
involvement in a p53-independent manner, which is associated
with the release of AIF and EndoG from mitochondria.42
Consistent with its tumourigenic function, SLC12A5 also
induces tumour invasion and metastasis. Ectopic expression of
SLC12A5 in colon cancer cell lines promoted cell migration and
invasion in vitro. Moreover, in a cancer metastasis mouse
model, depletion of SLC12A5 by shRNA in HCT116 cells sig-
niﬁcantly inhibited lung metastasis in vivo. The molecular
mechanisms by which SLC12A5 exerts its pro-invasive and pro-
metastasis functions in CRC were evaluated by cDNA micro-
array and immunoblotting. We revealed that the enhanced cell
invasion and migration by SLC12A5 were mediated via downre-
gulation of key antimetastasis genes, including MTSS1, p53,
NME1, FN1, NF2, FAT1, BRMS1, TIMP2 and CTSK, and upre-
gulation of the important pro-metastasis genes HGF, MMP10,
MMP13 and MMP2 (see online supplementary table S3). Of
which, MTSS1 plays a role in governing the metastatic nature of
breast cancer cells, as well as a prognostic indicator of disease-
free survival in patients with breast cancer.43 FN1 is a glycopro-
tein and is known to be involved in matrix remodelling, cell
adhesion and migration processes, which affect cell motility by
regulating actin polymerisation. The inhibitory effects of FN1
on cancer cell migration and metastasis have been well docu-
mented.44 45 MMP10, MMP13 and MMP2 are members of
extracellular proteinases with key functions in the formation
and remodelling of tumour invasion.46 47 HGF stimulates
tumour cell migration by binding speciﬁcally to its receptor
c-met in CRC.44 46–48 Taken together, SLC12A5 promoted
tumour metastasis through mediating key elements of the matrix
architecture such as MMP and ﬁbronectin.
A clinical association evaluation showed that overexpression
of SLC12A5 was associated signiﬁcantly with advanced tumour
stage (p<0.001). Patients with CRC vary greatly in clinical
outcome, depending on the growth status and aggressiveness of
tumours. At present, the most important clinical prognostic
indicator of disease outcome is TNM staging. Nevertheless,
some patients with CRC with low TNM stages are still afﬂicted
with disease recurrence. Therefore, additional prognostic bio-
markers are needed to provide better risk assessment. In this
regard, we further examined the inﬂuence of SLC12A5 overex-
pression on clinical outcomes of 195 patients with CRC. Both
univariate and multivariate cox regression analyses showing high
expression levels of SLC12A5 were correlated signiﬁcantly with
shortened overall survival, suggesting that SLC12A5 overexpres-
sion could be regarded as an independent new prognostic
marker for CRC.
In conclusion, ampliﬁcation of SLC12A5 is a common event
in CRC. Overexpression of SLC12A5 plays a pivotal oncogenic
role in colorectal carcinogenesis by inhibiting apoptosis through
mediating AIF-dependent and EndoG-dependent apoptotic sig-
nalling pathway and promoting metastasis by regulating key ele-
ments of the matrix architecture. SLC12A5 may serve as an
independent prognostic biomarker for patients with CRC.
Figure 7 Clinical signiﬁcance of SLC12A5 in colorectal cancers
(CRCs). Kaplan–Meier survival analysis according to SLC12A5
expression in195 patients with CRC. Patients with CRC with SLC12A5
overexpression had poorer survival than others. The difference is
statistically signiﬁcant based on the log-rank test (p=0.009).
Table 2 Cox regression analysis of potential poor prognostic factors for patients with colorectal cancer
Univariate analysis Multivariate analysis
Variable RR (95% CI) p Value RR (95% CI) p Value
Age 1.02 (0.99 to 1.05) 0.13 1.02 (0.99 to 1.05) 0.24
Gender
Male 0.88 (0.45 to 1.73) 0.70 0.78 (0.39 to 1.54) 0.45
Female 1.00 1.00
Location
Colon 0.57 (0.20 to 1.60) 0.28
Rectal 1.00
Grade
High or moderate 1.33 (0.66 to 2.68) 0.43
Low 1.00
TNM stage
I 0.06 (0.01 to 0.22) <0.001 0.07 (0.16 to 0.27) <0.001
II 0.19 (0.07 to 0.53) 0.001 0.28 (0.09 to 0.80) 0.017
III 0.53 (0.21 to 1.38) 0.19 0.69 (0.26 to 1.81) 0.45
IV 1.00 1.00
SLC12A5 expression in tumour tissues
High 2.38 (1.21 to 4.66) 0.01 2.30 (1.16 to 4.60) 0.018
Low 1.00 1.00
RR, relative risk; The TNM Staging System is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M).
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